Radiotherapy and concomitant chemoradiotherapy in the NB rat prostate adenocarcinoma model

The NB Rat Prostate Adenocarcinoma Model has been utilized to evaluate the effect of radiation therapy, chemotherapy, and the combination of these two modalities on growth of the androgen insensitive Nb AI-3 prostate tumor. These studies have demonstrated tumor regression in animals treated with Cyclophosphamide in combination with Cisplatin (p less than 0.05). Tumor regression was also seen in the groups treated with radiation therapy at doses of 600 cGy, twice weekly, for three weeks (p less than 0.05), 500 cGy, three times weekly, for three weeks (p less than 0.05), and 300 cGy, three times weekly, for three weeks (p less than 0.05). Complete tumor regression was seen in groups receiving 500 cGy, three times per week, for three weeks, concomitantly with fractional dose Cyclophosphamide and Cisplatin (p less than 0.001). Complete tumor regression was also seen in rats treated with radiation therapy at a dose of 300 cGy three times per week for three weeks concomitantly with fractional dose Cyclophosphamide and Cisplatin (p less than 0.001). Another group treated with radiation therapy alone at a dose of 750 cGy, one time weekly, for four weeks, demonstrated progression of tumor growth. All control and treatment groups demonstrated metastatic lesions with the exception of the group receiving 600 cGy twice weekly.